Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID™ Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme

NCT00083447 is registered in ClinicalTrials.gov with Xenova Biomedix as lead sponsor.

NCT NCT00083447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00083447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID™ Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme
Lead sponsor
Xenova Biomedix
Phase
Phase 3
Overall status
Withdrawn
Start date
May 31, 2004
Completion date
June 30, 2007
Enrollment
323
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme